Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Bromantane and Chlodantane — mechanism, dosing, side effects, legal status, and pricing.
Bromantane (Ladasten) is a synthetic adamantane-derivative small molecule — not a peptide — developed in Russia as an "actoprotector"/adaptogen with combined mild psychostimulant and anxiolytic activity. It is an approved prescription drug in Russia (Ladasten) for asthenic disorders, but it has no FDA or EMA approval and no blinded, placebo-controlled human trials. It is prohibited in sport (WADA S6 stimulant) and circulates on the gray market as a research chemical.
Chlodantane (ADK-910) is a non-peptide aryl-substituted 2-aminoadamantane amide, structurally related to bromantane and classified in Soviet pharmacological literature as an actoprotector/adaptogen. It has never been approved for human use in any jurisdiction and remains entirely unevaluated in clinical trials. All available data derive from animal and cell-culture experiments conducted in the former Soviet Union.
Bromantane
Chlodantane
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Bromantane
No pricing data yet.
Check Bromantane prices →Chlodantane
No pricing data yet.
Check Chlodantane prices →COA corpus from Disclosed Labs — independently tested batches only.
Bromantane
4
COAs
99.9%
Avg purity
3
Labs
Chlodantane
1
COAs
99.9%
Avg purity
1
Labs
Human evidence is limited to Russian clinical use of Ladasten. The largest published dataset is an open-label, non-comparative multicenter trial (28 centers, N=728) in asthenic disorder at 50–100 mg/day for 28 days (Voznesenskaia et al., 2010), reporting symptomatic improvement (CGI-S response 76.0%, CGI-I 90.8%) with adverse effects in ~3% of patients. No blinded, placebo-controlled randomized trial exists and there is no ClinicalTrials.gov registration. All mechanistic and toxicology data are preclinical (rat, mouse, in-vitro). Approved only in Russia; not FDA/EMA-approved; not a peptide.
Key references
No human data exist; a 2012 review explicitly states that all pharmacological data derive from animal or cell-culture experiments, with no clinical research conducted. In unspecified animal models, chlodantane enhanced resistance to physical and toxic-chemical stressors, produced immunostimulating effects in stress-induced immunodeficiency, and protected against hypoxia, high and low ambient temperature, and toxic chemical challenge. Effects were reported to appear after a single administration, and immunostimulant activity was described as more pronounced than that of bromantane.
Bromantane (Cognitive) and Chlodantane (Performance) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs